Benzinga | Jun 2, 2021 08:01AM EDT

Rain Therapeutics Announces Patient Referral Partnership For Planned MDM2-Amplified Phase 2 Basket Trial Of RAIN-32

Rain Therapeutics Inc. ("Rain"), a clinical-stage company developing precision oncology therapeutics, today announced a patient referral partnership with Caris Life Sciences ("Caris"). Under the terms of the partnership, Caris will provide patient referral services using their molecular intelligence (MI) trials platform for Rain's planned Phase 2 MDM2-amplified tumor-agnostic basket trial for RAIN-32, an oral MDM2 inhibitor in patients with certain solid tumors with pre-specified MDM2 amplification levels and wild type p53.



"We are thrilled to partner with Caris, a company that shares our precision oncology mission, to identify patients for our tumor agnostic, MDM2-amplified basket trial strategy," said Robert Doebele, M.D., Ph.D., co-founder, president and chief scientific officer of Rain. "Caris' whole exome and whole transcriptome tumor sequencing assays will be critical for enrollment for the Phase 2 study, which is expected to commence in the second half of 2021."

"Caris puts the patient at the center of everything we do, and we are pleased to partner with Rain on this novel tissue-agnostic clinical study," said Brian Lamon, Ph.D., Chief Business Officer, Head of BioPharma Business Development for Caris. "As the pioneer and industry leader in molecular profiling, this partnership builds upon our mission to save and extend patients' lives through the most comprehensive molecular and artificial intelligence available in the industry."